<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03384745</url>
  </required_header>
  <id_info>
    <org_study_id>AV002</org_study_id>
    <nct_id>NCT03384745</nct_id>
  </id_info>
  <brief_title>A Phase 2b Study of the Efficacy, Safety, and Tolerability of M1095 in Subjects With Moderate to Severe Psoriasis</brief_title>
  <official_title>A Phase 2b Randomized, Double-blind, Placebo Controlled, Multi-center 12-week Study With an Additional 40-week Follow-up Assessment of Efficacy, Safety and Tolerability of M1095 in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bond Avillion 2 Development LP</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Avillion LLP</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Bond Avillion 2 Development LP</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center phase 2b study in subjects with moderate to severe chronic plaque-type
      psoriasis. Approximately 300 subjects will be enrolled at approximately 60 investigator sites
      in North America and Europe.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 1, 2018</start_date>
  <completion_date type="Anticipated">August 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Investigator's Global Assessment (IGA)</measure>
    <time_frame>Week 12, as compared to Week 0 (baseline)</time_frame>
    <description>IGA score of 0 or 1, with an IGA reduction of at least 2 points from baseline. IGA is the Investigator's assessment of the extent of psoriasis, with 0 = clear of psoriasis, 1 = almost clear, 2 = mild psoriasis, 3 = moderate psoriasis, and 4 = severe psoriasis (the worst assessment on this scale).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Psoriasis Area and Severity Index (PASI)</measure>
    <time_frame>Week 12, as compared to Week 0 (baseline)</time_frame>
    <description>PASI 75, i.e. a subject's psoriasis has cleared by 75% or more at Week 12, compared to baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Psoriasis Area and Severity Index (PASI)</measure>
    <time_frame>Week 12, as compared to Week 0 (baseline)</time_frame>
    <description>PASI 100, i.e. a subject's psoriasis has completely cleared at Week 12, compared to baseline.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>M1095 30mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>M1095, 30 mg, given at Week 0, 2, 4, 8, 12 and every four weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>M1095 60mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>M1095, 60 mg, given at Week 0, 2, 4, 8, 12 and every four weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>M1095 120mg - regimen 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>M1095, 120 mg, given at Week 0, 2, 4, 8, 12 and every eight weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>M1095 120mg - regimen 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>M1095, 120 mg, given at Week 0, 2, 4, 6, 8, 10, 12 and every four weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo / M1095 120mg</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo, given at Week 0, 1, 2, 3, 4, 6, 8 and 10, then M1095, 120mg, given at Week 12, 14, 16, and every four weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Secukinumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Secukinumab, 300mg, given at Week 0, 1, 2, 3, 4, 8, 12 and every four weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>M1095</intervention_name>
    <description>M1095 is a trivalent monomeric nanobody® that neutralizes interleukins IL-17A, IL-17F, and IL-17A/F.</description>
    <arm_group_label>M1095 30mg</arm_group_label>
    <arm_group_label>M1095 60mg</arm_group_label>
    <arm_group_label>M1095 120mg - regimen 1</arm_group_label>
    <arm_group_label>M1095 120mg - regimen 2</arm_group_label>
    <arm_group_label>Placebo / M1095 120mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo contains no active drug.</description>
    <arm_group_label>Placebo / M1095 120mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Secukinumab</intervention_name>
    <description>Secukinumab is a human immunoglobulin G1 (IgG1) monoclonal antibody that selectively binds IL-17A.</description>
    <arm_group_label>Secukinumab</arm_group_label>
    <other_name>Cosentyx®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male and female subjects between 18 and 75 years of age.

          2. Moderate to severe plaque-type psoriasis for at least 6 months.

          3. Subject is a candidate for systemic biologic therapy.

          4. Subject has IGA ≥3, involved body surface area (BSA) ≥10%, and PASI ≥12 at screening
             and at baseline.

          5. Subject is able to comply with the study procedures.

          6. Subject must provide informed consent.

        Exclusion Criteria (Main):

          1. Non-plaque type psoriasis, drug-induced psoriasis, or other skin conditions (e.g.,
             eczema). (Psoriatic arthritis is allowed).

          2. Other medical conditions, including planned surgery or active infection / history of
             infection, as defined in the study protocol. Subjects will be screened for
             tuberculosis and hepatitis B / hepatitis C.

          3. Laboratory abnormalities at screening, as defined in the study protocol.

          4. Prior use of systemic or topical treatments for psoriasis, as defined in the study
             protocol.

          5. Prior use of any compound targeting IL-17, more than two biologic therapies,
             ustekinumab within 6 months, or TNF targeting therapies within 12 weeks.

          6. History of suicidal thoughts within 12 months.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 20, 2017</study_first_submitted>
  <study_first_submitted_qc>December 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 27, 2017</study_first_posted>
  <last_update_submitted>January 4, 2018</last_update_submitted>
  <last_update_submitted_qc>January 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

